Altimmune Set to Engage at Upcoming Life Sciences Conference

Author: Olivia Taylor Updated: 04-30-2025 07:51 AM

Altimmune Engaging at the Life Sciences Conference

GAITHERSBURG, Md. — Altimmune, Inc. (Nasdaq: ALT), a prominent player in the biopharmaceutical industry, is excited to announce an upcoming participation in a dynamic fireside chat at the Citizens Life Sciences Conference. This engagement offers a remarkable opportunity to showcase the company's innovative approach to developing next-generation therapeutics.

Conference Details

During the conference, members of Altimmune’s management team will present valuable insights into the exciting developments within the company. They will discuss their unique peptide-based therapeutics aimed at tackling critical health challenges. The session promises to be interactive and is scheduled for the morning on the designated date.

Accessing the Webcast

The session will be available via webcast, allowing interested parties to tune in and gain insights into Altimmune's advancements. To join the discussion, attendees can visit the Events section on the Altimmune website for access to the live stream.

About Altimmune

Altimmune is at the forefront of biopharmaceutical innovation, focusing on creating breakthrough peptide-based therapeutics. One of their standout developments includes pemvidutide, a GLP-1/glucagon dual receptor agonist designed to address obesity, metabolic dysfunction, and alcohol-related disorders. This strategic focus underscores Altimmune's commitment to pioneering effective treatments for emerging health trends.

Continuous Innovation

As the company progresses, Altimmune remains dedicated to refining its research and clinical methodologies, aiming to enhance patient outcomes on a global scale. The commitment to quality and efficacy is a hallmark of Altimmune's operational ethos.

Contact Information

For those wanting to delve deeper into the company's projects or engage with their team, Altimmune provides several channels for contact. Main inquiries can be directed to Greg Weaver, the Chief Financial Officer, at the provided phone number. Additionally, for investors, Lee Roth from Burns McClellan stands as a point of contact.

Follow Altimmune's Journey

Stakeholders and enthusiasts can follow Altimmune on social media platforms such as LinkedIn and Twitter for real-time updates and insights into their innovative work. This accessibility helps foster a community focused on advancement in biopharmaceuticals and patient care.

Frequently Asked Questions

What is the upcoming conference Altimmune is attending?

Altimmune will participate in the Citizens Life Sciences Conference, engaging in discussions about their innovative therapeutics.

How can I participate in the conference?

You can access the conference webcast by visiting the Events section on Altimmune’s website.

What specific therapies is Altimmune focusing on?

Altimmune is concentrating on next-generation peptide-based therapies, particularly pemvidutide for conditions like obesity and metabolic disorders.

Who can I contact for more information about Altimmune?

For inquiries, you can contact Greg Weaver, the CFO, or reach out to investor relations through Lee Roth at Burns McClellan.

How can I keep up with Altimmune's updates?

Follow Altimmune on LinkedIn and Twitter for the latest news and developments about their work and contributions to biopharmaceuticals.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.